Add this suggestion to a batch that can be applied as a single commit.
This suggestion is invalid because no changes were made to the code.
Suggestions cannot be applied while the pull request is closed.
Suggestions cannot be applied while viewing a subset of changes.
Only one suggestion per line can be applied in a batch.
Add this suggestion to a batch that can be applied as a single commit.
Applying suggestions on deleted lines is not supported.
You must change the existing code in this line in order to create a valid suggestion.
Outdated suggestions cannot be applied.
This suggestion has been applied or marked resolved.
Suggestions cannot be applied from pending reviews.
Suggestions cannot be applied on multi-line comments.
Suggestions cannot be applied while the pull request is queued to merge.
Suggestion cannot be applied right now. Please check back later.
Description of proposed changes
(Code changes @corneliusroemer, elevation reasons contributed by @trvrb)
This PR elevates Pango lineage XBB to Nextstrain clade 22F. Per cov-lineages.org, XBB is a "recombinant lineage of BJ.1 and BA.2.75 with breakpoint in S1". It possesses spike mutations:
V83A, H146Q, Q183E, V210I, G213E, R346T, L368I, V445P, F486S, F490S
XBB is now at 19% frequency in Asia in the standard 2m Asia-focused ncov build:
Applying the method from Figgins and Bedford, we estimate frequencies in Bangladesh, India and Singapore are now at 98%, 49% and 93% respectively:
And simple logistic growth rates have followed 0.21, 0.05 and 0.17 per day respectively.
If we look more broadly, we observe equivalent growth rates between BQ.1 and XBB in regions where they are co-circulating, this being Australia and the US.
It's too early to say whether BQ.1 or XBB will have a larger global impact, however, it's now clear that XBB meets our criteria 4 for designating a Nextstrain clade, namely:
Edited by @trvrb Oct 23, 2022
Testing
Trial build results are available at https://nextstrain.org/staging/ncov/gisaid/trial/xbb-is-22F/asia/2m, etc...